Terns Pharmaceuticals announced positive data from the ongoing CARDINAL trial of TERN-701 for CML patients at the ASH meeting. The study showed a 64% MMR achievement rate in all patients at 24 weeks and a 75% MMR achievement rate in patients at doses >320mg QD. The safety profile was encouraging with a longer treatment duration. The company will host an investor update call today at 4:30pm ET. TERN-701 demonstrated potential as a best-in-disease therapy for CML patients, showing high response rates and favorable safety. The study enrolled 63 patients, with 87% remaining on treatment.

Read more at GlobeNewswire: Terns Highlights Additional Positive Phase 1 Clinical Data